ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.90%58.570.0%$919.92m
AMGNAmgen, Inc. 1.22%258.241.3%$759.50m
GILDGilead Sciences, Inc. 0.38%76.351.0%$735.36m
REGNRegeneron Pharmaceuticals, Inc. 2.18%622.452.5%$672.88m
NVAXNovavax, Inc. 2.43%81.64102.0%$616.96m
BIIBBiogen, Inc. 0.13%265.121.6%$544.40m
VRTXVertex Pharmaceuticals, Inc. 1.68%291.101.9%$526.40m
ILMNIllumina, Inc. 1.24%373.103.5%$309.63m
ALXNAlexion Pharmaceuticals, Inc. -0.08%112.302.0%$225.16m
BMRNBioMarin Pharmaceutical, Inc. 0.75%126.784.3%$216.16m
SGENSeattle Genetics, Inc. 0.90%169.036.1%$202.76m
SRNESorrento Therapeutics, Inc. -1.15%6.851.8%$187.20m
SRPTSarepta Therapeutics, Inc. -1.77%162.7513.9%$164.07m
INCYIncyte Corp. 3.72%106.472.5%$163.74m
IMMUImmunomedics, Inc. 1.71%37.5413.3%$157.98m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.